- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Rathore Wins Thought Leader Award for Biosimilar Characterization
Anurag S. Rathore, PhD, wins a grant and the use of scientific instruments from Agilent to further his investigation.
Anurag S. Rathore, PhD, has become the first from India to receive the Agilent Technologies Thought Leader Award. Rathore was recognized for his contributions to biopharmaceutical research and his efforts to advance the molecular characterization of biosimilars.
The characterization of biosimilars is a process that helps determine the bioequivalence of these products to reference, or original, drugs. Characterization also establishes the nature and extent of differences between biosimilar candidates and their reference products and whether these are clinically meaningful.
As recipient of the award, Rathore receives Agilent equipment and a grant to support his research. He joins 47 others who have received the Agilent awards previously.
Agilent, a 1999 spinoff from Hewlett-Packard, is a Santa Clara, California–based analytical instrumentation developer and manufacturer.
Rathore is a professor and scientist at the Indian Institute of Technology (IIT) Delhi. He earned his PhD from Yale University and currently works in the Department of Chemical Engineering at ITT Delhi. He is a member of the Parenteral Drug Association and American Chemical Society and is the author of more than 400 publications and presentations. He is also editor-in-chief of Preparative Biochemistry and Biotechnology. Information about his publications can be accessed by clicking here.
Rathore recently spoke with The Center for Biosimilars® about a study he conducted on reasons that applications for biosimilar regulatory approval fail.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
